Molecular diversity of the PDAC

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors of all. The five-year survival rate is still in the single digits. In recent years, however, there has been a paradigm shift: PDAC is no longer seen as a uniform disease, but as an ensemble of different molecular subtypes with clearly distinguishable biology. New genome, transcriptome, proteome, metabolome and immunome analyses are fundamentally changing our understanding of these tumors – and opening up prospects for more precise, individually targeted therapy.